Advertisement

Medical Oncology

, 33:54 | Cite as

Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer

  • Asta ByeEmail author
  • Nima Wesseltoft-Rao
  • Per Ole Iversen
  • Grete Skjegstad
  • Kirsten B. Holven
  • Stine Ulven
  • Marianne J. Hjermstad
Original Paper

Abstract

Chronic systemic inflammatory response is proposed as an underlying mechanism for development of cancer cachexia. We conducted a prospective study to examine changes in inflammatory biomarkers during the disease course and the relationship between inflammatory biomarkers and cachexia in patients with inoperable pancreatic cancer. Twenty patients, median (range) age 67.5 (35–79) years, 5 females, were followed for median 5.5 (1–12) months. Cachexia was diagnosed according to the 2011 consensus-based classification system (weight loss >5 % past six months, BMI < 20 kg/m2 and weight loss >2 %, or sarcopenia) and the modified Glasgow Prognostic score (mGPS) that combines CRP and albumin levels. Inflammatory biomarkers were measured by enzyme immunoassays. The patients had increased levels of most inflammatory biomarkers, albeit not all statistically significant, both at study entry and close to death, indicating ongoing inflammation. According to the consensus-based classification system, eleven (55 %) patients were classified as cachectic upon inclusion. They did not differ from non-cachectic patients with regard to inflammatory biomarkers or energy intake. According to the mGPS, seven (35 %) were defined as cachectic and had a higher IL-6 (p < 0.001) than the non-cachectic patients. They also had a slightly, but insignificantly longer survival than non-cachectic patients (p = 0.08). The mGPS should be considered as an additional framework for identification of cancer cachexia.

Keywords

Advanced cancer Pancreatic cancer Cancer cachexia Inflammation Cytokines Adipokines 

Notes

Acknowledgments

The entire data collection was carried out at the Departments of Surgery, Oncology and Palliative Care at Oslo University Hospital. Appreciation is expressed to the staff of the study and to patients who participated.

Funding

This study was funded by Oslo and Akershus University College of Applied Sciences and Hole’s trust fund.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. doi: 10.3322/CA.2007.0010.CrossRefPubMedGoogle Scholar
  2. 2.
    Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg. 2011;15(11):1917–27. doi: 10.1007/s11605-011-1665-9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer. 1997;75(1):106–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26(2):146–51. doi: 10.1097/MOG.0b013e3283347e77.CrossRefPubMedGoogle Scholar
  5. 5.
    Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. doi: 10.1016/S1470-2045(10)70218-7.CrossRefPubMedGoogle Scholar
  6. 6.
    Hopkinson JB, Wright DN, McDonald JW, Corner JL. The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. J Pain Symptom Manage. 2006;32(4):322–31. doi: 10.1016/j.jpainsymman.2006.05.012.CrossRefPubMedGoogle Scholar
  7. 7.
    Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–9. doi: 10.1016/j.clnu.2008.06.013.CrossRefPubMedGoogle Scholar
  8. 8.
    Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev. 2014;40(6):685–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P, et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol. 2011;80(1):114–44. doi: 10.1016/j.critrevonc.2010.10.004.CrossRefPubMedGoogle Scholar
  10. 10.
    Gulen ST, Karadag F, Karul AB, Kilicarslan N, Ceylan E, Kuman NK, et al. Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung. 2012;190(3):327–32.CrossRefPubMedGoogle Scholar
  11. 11.
    Roxburgh CSD, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110(6):1409–12. doi: 10.1038/bjc.2014.90.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Cesari M, Penninx BWJH, Pahor M, Lauretani F, Corsi AM, Williams GR, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol Ser A Biol Sci Med Sci. 2004;59(3):M242–8. doi: 10.1093/gerona/59.3.M242.CrossRefGoogle Scholar
  13. 13.
    Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88(3):625–36. doi: 10.1016/j.critrevonc.2013.07.015.CrossRefPubMedGoogle Scholar
  14. 14.
    Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, Giese T, et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res. 2005;11(16):5802–8. doi: 10.1158/1078-0432.CCR-05-0185.CrossRefPubMedGoogle Scholar
  15. 15.
    Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21(5):331–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–64.CrossRefPubMedGoogle Scholar
  17. 17.
    Klepstad P, Kaasa S. The importance and pitfalls of correlational science in palliative care research. Curr Opin Support Palliat Care. 2012;6(4):508–13. doi: 10.1097/SPC.0b013e32835a0c70.CrossRefPubMedGoogle Scholar
  18. 18.
    Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–6. doi: 10.1158/1078-0432.CCR-08-2242.CrossRefPubMedGoogle Scholar
  19. 19.
    Wesseltoft-Rao N, Holven KB, Telle-Hansen VH, Narverud I, Iversen PO, Hjermstad MJ, et al. Measurements of body fat is associated with markers of inflammation, insulin resistance and lipid levels in both overweight and in lean, healthy subjects. e-SPEN Journal. 2012;7(6):e234–40. doi: 10.1016/j.clnme.2012.10.002.CrossRefGoogle Scholar
  20. 20.
    Lillegaard IT, Andersen LF. Validation of a pre-coded food diary with energy expenditure, comparison of under-reporters v. acceptable reporters. Br J Nutr. 2005;94(6):998–1003.CrossRefPubMedGoogle Scholar
  21. 21.
    Blaker B, Aarsland M. Mål og vekt for matvarer. Oslo: Landsforeningen for Kosthold & Helse; 1989. p. 6–41.Google Scholar
  22. 22.
    Thomas B. Manual of dietetic practice. 2nd ed. Oxford: Blacwell; 1994.Google Scholar
  23. 23.
    van der Meij BS, Schoonbeek CP, Smit EF, Muscaritoli M, van Leeuwen PA, Langius JA. Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks. Br J Nutr. 2013;109(12):2231–9. doi: 10.1017/S0007114512004527.CrossRefPubMedGoogle Scholar
  24. 24.
    Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003;56(10):968–76. doi: 10.1016/S0895-4356(03)00170-7.CrossRefPubMedGoogle Scholar
  25. 25.
    Seelaender M, Batista M Jr, Lira F, Silverio R, Rossi-Fanelli F. Inflammation in cancer cachexia: to resolve or not to resolve (is that the question?). Clin Nutr. 2012;31(4):562–6. doi: 10.1016/j.clnu.2012.01.011.CrossRefPubMedGoogle Scholar
  26. 26.
    Bilir C, Engin H, Can M, Temi Y, Demirtas D. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. Med Oncol. 2015;32(3):1–6. doi: 10.1007/s12032-015-0497-y.CrossRefGoogle Scholar
  27. 27.
    Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90(5):2920–6. doi: 10.1210/jc.2004-1788.CrossRefPubMedGoogle Scholar
  28. 28.
    Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S, Dulger AC, et al. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol. 2010;8:85. doi: 10.1186/1477-7819-8-85.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, et al. Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer. 2006;15(1):39–46. doi: 10.1007/s00520-006-0091-0.CrossRefPubMedGoogle Scholar
  30. 30.
    Bye A, Jordhoy MS, Skjegstad G, Ledsaak O, Iversen PO, Hjermstad MJ. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013;21(1):219–27. doi: 10.1007/s00520-012-1514-8.CrossRefPubMedGoogle Scholar
  31. 31.
    Yavuzsen T, Walsh D, Davis MP, Kirkova J, Jin T, LeGrand S, et al. Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia. Support Care Cancer. 2009;17(12):1531–41. doi: 10.1007/s00520-009-0623-5.CrossRefPubMedGoogle Scholar
  32. 32.
    Wesseltoft-Rao N, Hjermstad MJ, Ikdahl T, Dajani O, Ulven SM, Iversen PO, et al. Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer. Nutr Cancer. 2015;67(3):472–80.CrossRefPubMedGoogle Scholar
  33. 33.
    Kyrana E, Briggs S, Dhawan A. Molecular mechanisms of cachexia in chronic disease. Expert Rev Endocrinol Metab. 2012;7(1):73–90. doi: 10.1586/eem.11.87.CrossRefGoogle Scholar
  34. 34.
    Gordon JN, Green SR, Goggin PM. Cancer cachexia. Q J Med. 2005;98:779–88. doi: 10.1093/qjmed/hci127.CrossRefGoogle Scholar
  35. 35.
    Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int. 2014;13(4):371–80. doi: 10.1016/S1499-3872(14)60259-9.CrossRefPubMedGoogle Scholar
  36. 36.
    Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma. Cancer. 2004;101(12):2727–36. doi: 10.1002/cncr.20672.CrossRefPubMedGoogle Scholar
  37. 37.
    Scheede-Bergdahl C, Watt HL, Trutschnigg B, Kilgour RD, Haggarty A, Lucar E, et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin Nutr. 2012;31(1):85–8. doi: 10.1016/j.clnu.2011.07.010.CrossRefPubMedGoogle Scholar
  38. 38.
    Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009;20(5):625–33. doi: 10.2307/40272028.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006;106(4):966–73. doi: 10.1002/cncr.21690.CrossRefPubMedGoogle Scholar
  40. 40.
    Creutzberg EC, Wouters EFM, Vanderhoven-Augustin IML, Dentener MA, Schols AMWJ. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(4):1239–45. doi: 10.1164/ajrccm.162.4.9912016.CrossRefPubMedGoogle Scholar
  41. 41.
    Li M-D. Leptin and beyond: an odyssey to the central control of body weight. Yale J Biol Med. 2011;84(1):1–7.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Schautz B, Later W, Heller M, Peters A, Müller MJ, Bosy-Westphal A. Impact of age on leptin and adiponectin independent of adiposity. Br J Nutr. 2012;108(02):363–70. doi: 10.1017/S0007114511005605.CrossRefPubMedGoogle Scholar
  43. 43.
    Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006;291(3):R674–R83. doi: 10.1152/ajpregu.00104.2006.CrossRefPubMedGoogle Scholar
  44. 44.
    Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care–correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;103(10):2189–98. doi: 10.1002/cncr.21013.CrossRefPubMedGoogle Scholar
  45. 45.
    Hall DT, Ma JF, Di Marco S, Gallouzi I-E. Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia. Aging (Albany NY). 2011;3(8):702–15.CrossRefGoogle Scholar
  46. 46.
    Vlachostergios PJ, Gioulbasanis I, Kamposioras K, Georgoulias P, Baracos VE, Ghosh S, et al. Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. Oncology. 2011;81(2):113–8. doi: 10.1159/000331685.CrossRefPubMedGoogle Scholar
  47. 47.
    Thoresen L, Fjeldstad I, Krogstad K, Kaasa S, Falkmer UG. Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med. 2002;16(1):33–42.CrossRefPubMedGoogle Scholar
  48. 48.
    Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57. doi: 10.1016/S0140-6736(04)15841-8.CrossRefPubMedGoogle Scholar
  49. 49.
    Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH. Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study. Support Care Cancer. 2006;14(11):1126–33. doi: 10.1007/s00520-006-0067-0.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Asta Bye
    • 1
    • 2
    Email author
  • Nima Wesseltoft-Rao
    • 1
    • 3
  • Per Ole Iversen
    • 3
    • 4
  • Grete Skjegstad
    • 1
  • Kirsten B. Holven
    • 3
    • 5
  • Stine Ulven
    • 1
    • 3
  • Marianne J. Hjermstad
    • 2
    • 6
  1. 1.Department of Nursing and Health Promotion, Faculty of Health SciencesOslo and Akershus University College of Applied SciencesOsloNorway
  2. 2.Regional Centre for Excellence in Palliative Care, Department of OncologyOslo University HospitalOsloNorway
  3. 3.Department of Nutrition, Institute of Basic Medical SciencesUniversity of OsloOsloNorway
  4. 4.Department of HematologyOslo University HospitalOsloNorway
  5. 5.Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Endocrinology, Morbid Obesity and Preventive MedicineOslo University HospitalOsloNorway
  6. 6.European Palliative Care Research Centre, Faculty of MedicineNorwegian University of Science and TechnologyTrondheimNorway

Personalised recommendations